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severity were observed between hospitalized Managed
Care patients or Indemnity patients.
CONCLUSIONS: Higher hospitalization rates was ob-
served in the Indemnity patients and may be the factor for
the higher overall asthma costs seen in this payer group.
DP3
USING SIMULATION MODELING TECHNIQUES 
TO FACILITATE THE MANAGEMENT OF THE 
WAITING LIST FOR LIVER TRANSPLANTATION
Ratcliffe J1,Young T1, Eldabi T2
1Health Economics Research Group, Brunel University, 
Uxbridge, UK; 2Centre for Applied Simulation Modelling, 
Department of Computer Sciences, Brunel University, 
Uxbridge, UK
OBJECTIVE: The purpose of the study was to evaluate
the clinical and economic impact of alternative decision
criteria in the management of the waiting list for liver
transplantation. The impact of changes in the timing of
transplantation for the average estimated net life expect-
ancy of the cohort studied and the overall cost-effective-
ness of the transplantation program at one London cen-
ter were investigated.
METHODS: A discrete event simulation model was de-
veloped to reflect the pattern and timing of care for pa-
tients accepted to the liver transplantation program. A
subsidiary simulation model was also developed to reflect
the pattern and timing of care received for patients re-
jected for liver transplantation. The models were con-
structed to predict changes in the net length of survival
(i.e., predicted survival with transplantation versus survival
without transplantation) and resources used for individual
patients according to the time at which transplantation ac-
tually occurred, and according to alternative times at which
transplantation may have occurred had the waiting list
been managed differently.
RESULTS: Using a 5-year time horizon the total cost per
life-year gained of the liver transplantation program was
£66,146 (CI £54,236–£75,688) using the current selec-
tion policy. It was found that the total cost per life-year
gained could be reduced by as much as 20% (£52,917,
CI £43,731–£59,298) if the less severely ill patients no
longer received priority for a donor organ.
CONCLUSIONS: The pursuit of efficiency in the provi-
sion of liver transplantation also needs to be reconciled
with the important issues of equity and fairness in donor
organ allocation. However, the results of this study sug-
gest that the overall cost-effectiveness of the liver trans-
plantation program could be improved if the current selec-
tion policy were modified to take account of the reduced
chances of success of the more severely ill patients.
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Cost of illness studies have two main uses: to measure
baseline outcomes and changes over time as a function of
changing inputs, and to generate new research hypotheses.
OBJECTIVES: To evaluate the usefulness of cost of ill-
ness studies by testing the likely validity of results.
METHODS: We reviewed all English-language, peer-
reviewed, US studies of specified diagnoses published 1
January 1985 to 31 December 1998. Studies were ob-
tained from MEDLINE and other computerized searching
systems. Direct and indirect costs were adjusted to 1992
dollars for sector-specific (e.g., hospital) inflation since
year of the study. Additional adjustments were made by
diagnosis for technological innovations. Cost comparisons
were made among multiple studies for the same illness.
RESULTS: Of the 1556 studies identified, only 179 met all
inclusion criteria. By diagnosis, cost of illness varied 2- to
10-fold even after adjustments for inflation and effects of
new technology. Such large, mainly nonsystematic, varia-
tions were found among all sectors of direct and indirect
costs. Large variations were due primarily to inconsistent
cost, resource and category definitions, methodology, and
data sources—whether or not study results were derived
nationally or based on population samples of disease inci-
dence and prevalence. The latter studies usually showed
substantially larger annual cost estimates and greater vari-
ation than the former.
CONCLUSION: Cost of illness studies are now of uncer-
tain a priori usefulness. Criteria need to be developed to
construct such studies so that they can be useful policy
and planning tools.
